Form 4: Replimune Group's Chief Medical Officer Sells Shares to Cover Tax Obligations

Konstantinos Xynos, Chief Medical Officer of Replimune Group, sold 6,367 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On May 16, 2024, Konstantinos Xynos, the Chief Medical Officer of Replimune Group, Inc., sold 6,367 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the partial vesting of his restricted stock units (RSUs).
• The shares were sold at a weighted average price of $6.47, with individual transactions ranging from $6.46 to $6.56 per share.
• Following the transaction, Xynos still beneficially owns 133,012 shares of Replimune Group's common stock.
• The sale was conducted according to an irrevocable 'sell to cover' provision in the RSU award agreements, indicating it was not a discretionary sale.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale for tax purposes, which is neutral in sentiment.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions, which can be informative but don't necessarily indicate a change in the company's overall prospects.

Key Dates